Adeno-associated virus vectors in clinical trials.

[1]  J. Clancy,et al.  Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. , 2004, Chest.

[2]  P. Laipis,et al.  Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors , 2001, Gene Therapy.

[3]  Jia Luo,et al.  Subthalamic GAD Gene Therapy in a Parkinson's Disease Rat Model , 2002, Science.

[4]  T. Flotte,et al.  Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus , 1999, The Laryngoscope.

[5]  James M. Wilson,et al.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Flotte,et al.  Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  G. Firestein.  Evolving concepts of rheumatoid arthritis , 2003, Nature.

[8]  Mary J. Connell,et al.  Novel Adeno-Associated Virus Vector Vaccine Restricts Replication of Simian Immunodeficiency Virus in Macaques , 2005, Journal of Virology.

[9]  S. Harper,et al.  Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  Philip R. Johnson,et al.  Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle , 2003, Journal of Virology.

[11]  Katherine A. High,et al.  Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector , 1999, Nature Medicine.

[12]  D. Eidelberg,et al.  Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. , 2001, Human gene therapy.

[13]  T. Flotte,et al.  Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. , 1996, Gene therapy.

[14]  D. Schadendorf,et al.  Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: evidence for a high transduction efficiency into primary epithelial cancer cells. , 1998, Human gene therapy.

[15]  S. Hunt.  Technology evaluation: anticancer gene therapy, MediGene. , 2001, Current opinion in molecular therapeutics.

[16]  R. Samulski,et al.  Integration of adeno-associated virus (AAV) and recombinant AAV vectors. , 2004, Annual review of genetics.

[17]  H. Voss,et al.  Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. , 2004, Human gene therapy.

[18]  R. Gibson,et al.  A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. , 2001, Human gene therapy.

[19]  Alan McClelland,et al.  Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.

[20]  A. Norbash,et al.  Maxillary sinusitis as a surrogate model for CF gene therapy clinical trials in patients with antrostomies , 1999, The journal of gene medicine.

[21]  Terence R Flotte,et al.  Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. , 2003, Human gene therapy.

[22]  T. Serikawa,et al.  Accumulation of N‐Acetyl‐L‐Aspartate in the Brain of the Tremor Rat, a Mutant Exhibiting Absence‐Like Seizure and Spongiform Degeneration in the Central Nervous System , 2000, Journal of neurochemistry.

[23]  T. Flotte,et al.  In vivo model of adeno-associated virus vector persistence and rescue , 1996, Journal of virology.

[24]  M. Feldmann,et al.  TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases , 2003, Nature Medicine.

[25]  M. Drumm,et al.  Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. , 1993, The Journal of biological chemistry.

[26]  Terence R Flotte,et al.  A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. , 2002, Human gene therapy.

[27]  B. Carter.  Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[29]  T. Flotte,et al.  Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  J. Biegel,et al.  Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  R. Kaul,et al.  Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease , 2000, Annals of neurology.

[32]  R. Mandel,et al.  Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  S. Wahl,et al.  Intraarticular gene transfer of TNFR:Fc suppresses experimental arthritis with reduced systemic distribution of the gene product. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  D. Shera,et al.  Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. , 2002, Human gene therapy.

[35]  T. Flotte,et al.  Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus , 1998, The Lancet.

[36]  M. Kay,et al.  Efficient lentiviral transduction of liver requires cell cycling in vivo , 2000, Nature Genetics.

[37]  T. Flotte,et al.  Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  T. Skopek,et al.  International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. , 1994, Mutation research.

[39]  R. Buhmann,et al.  Gene transfer of costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response , 1997, Gene Therapy.

[40]  E. Bruckheimer,et al.  Secretion of a TNFR:Fc Fusion Protein following Pulmonary Administration of Pseudotyped Adeno-Associated Virus Vectors , 2004, Journal of Virology.

[41]  T. Flotte,et al.  Repeated Delivery of Adeno-Associated Virus Vectors to the Rabbit Airway , 1999, Journal of Virology.

[42]  T. Flotte,et al.  Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.

[43]  J. Mendell,et al.  Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. , 2000, Human gene therapy.

[44]  R. Herzog,et al.  Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. , 2002, Blood.

[45]  H. Mizukami,et al.  A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus. , 2001, Human gene therapy.

[46]  Bing Wang,et al.  Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart , 2005, Nature Biotechnology.

[47]  Alan McClelland,et al.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.

[48]  T. Flotte.  Immune responses to recombinant adeno-associated virus vectors: putting preclinical findings into perspective. , 2004, Human gene therapy.